• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen touts lowered prices for Repatha delivery devices

January 8, 2019 By Sarah Faulkner

Amgen updated logoAmgen (NSDQ:AMGN) said today that it lowered the list prices of the drug-delivery devices for its cholesterol drug, Repatha, to $5,850 per year.

The Thousand Oaks, Calif.-based company touted the 60% discount as a way to boost patient affordability and accessibility.

The Repatha SureClick autoinjector, which Amgen said is the most commonly used delivery device for Repatha, was discounted to $5,850 in October last year.

“Every 40 seconds someone in America has a heart attack or stroke making cardiovascular disease one of the country’s most significant health challenges,” Murdo Gordon, Amgen’s EVP of global commercial operations, said in prepared remarks.

“Repatha can help to address this significant public health issue, which is why we are working hard to improve patient affordability by lowering Repatha’s list price to improve patient co-pays, especially for Medicare patients,” he said.

The company reported that 80% of current Repatha Medicare patients have access to Repatha at the new list price.

“The lower list price announced in October has been received very positively by patients, physicians and payers, and we are already seeing a noticable impact for patients,” Gordon added. “However, more must be done to help more patients get to a low fixed co-pay. We need continued engagement from all stakeholders – from healthcare professionals to payers to plans and to government agencies – to help ensure patients benefit from the lower list price to reduce their out-of-pocket costs.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS